mRNA medicines hold enormous promise for drugging targets outside the reach of classic small molecules. Here, the authors develop a modular platform to design programmable mRNA therapeutics that act by modifying epigenetic state.
- Charles W. O’Donnell
- Jeremiah D. Farelli
- Thomas G. McCauley
